Do you offer hypofractionated accelerated whole breast radiation therapy for women receiving trastuzumab during RT, particularly those with left sided primaries?   

In START B ~ 23 % of women received some form of cytotoxic chemotherapy, and the trial was conducted in the trastuzumab era, but there is no mention of trastuzumab specifically in the publication.  Is there any other available data to help guide us in this?



Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Academic Institution